The Pattern of Ectopic Hormone Production in Lung Cancer

PHILIP K. BONDY, M.D.

West Haven V.A. Medical Center, West Haven, Connecticut, and the Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut

Pulmonary cancers produce many hormonal polypeptides. There is a tumor-specific pattern to the appearance of abnormal adrenal function and inappropriate secretion of vasopressin, which are frequently found in small cell undifferentiated carcinoma but occur only very rarely, if at all, in squamous tumors. Humoral hypercalcemia, on the other hand, occurs almost entirely in squamous tumors and is rarely if ever seen in small cell or large cell tumors or in adenocarcinoma. In contrast, "big ACTH" and beta lipotropin are found in the plasma and tumor extracts of lung cancers of all types. Calcitonin and the beta chain of human chorionic gonadotropin are also found in the plasma of a considerable portion of patients with all histological types of lung cancers.

The association of certain pulmonary neoplasms with hormonal syndromes has been recognized for at least 50 years [1], and the fact that such syndromes result from release of polypeptide hormones by the tumor has been known for at least two decades [2,3]. The fact that the hormones originate in tumors arising in tissue which does not usually secrete endocrine substances led to their being called "ectopic" [4]. Since the discovery of this property of tumors, an immense literature has built up, reporting individuals or small groups of patients with the syndromes produced by ectopic hormones. Within the past five years or less, the possibility of utilizing the production of such hormones as markers in diagnosing pulmonary tumors and following their response to treatment has led to active interest in the levels of these substances in the plasma of patients with pulmonary neoplasms. It is somewhat surprising, therefore, that very few studies have been published in which an attempt has been made to study populations of patients with carcinoma of the lung in order to determine the distribution and frequency of the production of hormones by tumors of various types. In this paper an attempt is made to survey the present state of the problem in order to determine whether there is a characteristic distribution pattern of hormones produced by lung tumors according to their histological classification. The question of whether measurement of such hormones is helpful in following the clinical course of the patients will not be discussed, since it has been considered elsewhere [5,6].

The literature was surveyed for studies in which an attempt had been made to investigate all patients with carcinoma of the lung entering the clinic or hospital. In some instances, the survey was limited to a particular type of tumor (usually small

181

Presented at the Symposium on Pulmonary Neoplasms: Review of Current Status, VA Medical Center, West Haven, CT, July 30-August 1, 1980.
Address reprint requests to: Philip K. Bondy, M.D., 151, West Haven VA Medical Center, West Haven, CT 06516
Copyright © 1981 by The Yale Journal of Biology and Medicine, Inc.
All rights of reproduction in any form reserved.
cell undifferentiated carcinoma) and these were accepted provided it appeared that all patients with the diagnosis had been included. Reports were rejected if the authors had investigated only or chiefly patients with clinical endocrine syndromes, or if the histological classification of the patients was not indicated.

In many instances the survey was limited to measurement of plasma hormones by radioimmuno- or bioassay, but in others physiological investigations were also used to seek evidence for abnormal control of such variables as plasma cortisol, serum calcium concentration and plasma, and urine osmolality or urine volume. The diagnosis of abnormal adrenal cortical control was based on loss of diurnal variation or suppressibility of plasma cortisol concentration with dexamethasone. The diagnosis of SIADH was based on hemodilution combined with high urinary osmolality.

The results are shown in the tables. Table 1 shows the frequency with which abnormalities of adrenal function, vasopressin secretion, calcium concentration, plasma calcitonin, and beta HCG were observed in each histological type of tumor. Note that abnormal adrenal function and SIADH were observed very frequently in small cell tumors and never in squamous tumors, whereas hypercalcemia was common in squamous but absent in small cell neoplasms. Calcitonin and hCG were often increased in all types of tumors.

Ever since the work of Gerwirtz and Yalow [8] there has been interest in whether metabolic precursors of ACTH such as “big” ACTH or beta lipotropin might be useful as tumor markers. Table 2 shows the results of studies using the special methods necessary for detection of these moieties. Because Yalow's group has been interested in comparing tumor and plasma levels, they have not studied many patients with small cell tumors. Surgery is seldom performed in this group, so tissue adequate for measuring tumor hormone concentration is seldom available. The limited number of small cell tumors reported in the table reflects this research strategy [9].

Table 1 probably presents a minimal value for the incidence of the abnormalities mentioned, because most surveys obtained their data on only one occasion during the patients' course. An abnormality developing at some other time during the disease might therefore have been missed. Moreover, some abnormalities are demonstrable only after tests which stress or manipulate the system under study. For example, the incidence of the syndrome of inappropriate vasopressin secretion (SIADH) may become apparent only when a patient with mildly depressed plasma osmolality is subjected to a water load [12]. Surveys depending entirely on a single measurement of ACTH concentration may be misleading. It is well known that the plasma ACTH normally varies rapidly over a wide range, so even in a patient ordinarily having a slightly elevated hormone concentration it is possible that a single determination might fall within the normal range. Moreover, if a substantial portion of the circulating ACTH originates in the tumor, the normal control mechanisms producing diurnal rhythmicity and feedback suppression might be lost although total ACTH is within normal limits [11,12]. ACTH samples obtained late in the day should have a higher discriminating value than those taken early in the morning because of diurnal variation of normal pituitary secretion of ACTH, but Yalow's group [9] seems to be the only one taking advantage of this fact.

Experienced pathologists often disagree in classifying tumors, especially when the specimen contains more than one type of tissue. The differentiation of a highly anaplastic squamous tumor from a small cell cancer may occasionally depend on the presence of only a few strands of keratin. Whether such a tumor ends up in the small cell or squamous category depends to some extent on whether the pathologist bases
| Hormone               | Cell Type | References |
|-----------------------|-----------|------------|
|                      | Small Cell|            |
| ACTH                  | Adenocarcinoma | [6, 10, 11, 12] |
|                      | Large Cell |            |
| Abnormal control      | Squamous   |            |
| pattern               |            |            |
| or ACTH > 80 pg/ml    | 0/36       |            |
| Ectopic ACTH Syndrome | 9/202 (9%) |            |
| Vasopressin           | 0/18       |            |
| Calcitonin            | 28/137 (20%) |            |
| Hypercalcemia         | 0/112      |            |
| Humoral metastases    | 15/60 (25%) |            |
| beta-HCG              | 11/45 (24%) |            |

* Bondy PK: Unpublished data.
his classification on the most differentiated portion of the tumor or on the average appearance. Electron microscopy may be valuable in identifying the “APUD” cells which produce the small cell secretory pattern [23], but most authors did not mention using this modality.

Considering these problems, it is interesting that the histological classification of types of pulmonary neoplasms in several different clinical centers produced such a clear pattern of association of abnormal adrenal control, SIADH, and humoral hypercalcemia with specific types of tumors. It appears that these three determinations can discriminate between small cell and squamous tumors, and could be used to bolster a diagnosis based on histology or to predict the histology (and therefore the response to treatment) if tissue is not available. The hormones appear to be of less differential value in adenocarcinoma, but the number of observations is small. Calcitonin is not of much value in differential diagnosis, although it has been recommended for following the response to treatment [6]. It should also be remembered that many of these hormones may be increased for other causes than secretion by the tumor. SIADH can be caused by nonmalignant disease of the lungs, especially infection [24] and ACTH is secreted in response to a variety of stresses [25].

There is general agreement that in patients with carcinoma of the lung the syndrome of ectopic ACTH production occurs mainly, if not uniquely, in small cell tumors. The data in Table 2 are interesting, therefore, because they suggest that all lung tumors contain and may release a non-functional form of ACTH, which may be a pro-ACTH (“big” ACTH) or the larger precursor polypeptide, beta lipotropin. This polypeptide includes ACTH in its amino acid sequence together with the endorphins and melanocyte stimulating activity. Aside from its ability to produce darkening of the skin, beta lipotropin is not known to have any physiological activity, in spite of the powerful effects produced by its fragments. It is possible that most lung tumors can produce the precursor but only the small cell tumor can break it down to functional units [26]. In any case, there is a clear clinical difference between the probable diagnosis of small cell tumor in the presence of an abnormality of adrenal function and the demonstration of some form of “big” ACTH or beta lipotropin [9,11,27] in the plasma of patients with lung tumors regardless of histological type. The general presence of “big” ACTH in all types of lung cancer is reminiscent of the beta chain of human chorionic gonadotropin, which has been found in an ineffective form in normal tissue and most tumors [29] and may therefore be of some value in diagnosing cancer, but not in distinguishing one tumor from another.

REFERENCES

1. Brown WH: A case of pluriglandular syndrome: Diabetes of bearded women. Lancet 2:1022–1023, 1928

Table 2
“Big” ACTH and beta LPH as Markers of Lung Cancer

| Cell Type         | ACTH > 100 pg/ml | beta LPH > 60 pg/ml |
|-------------------|------------------|---------------------|
|                   | No. positive     | No. examined | % positive | No. positive | No. examined | % positive |
| Small Cell        | 17               | 27          | 63        | 13           | 24          | 54        |
| Squamous          | 79               | 86          | 92        | 10           | 30          | 33        |
| Adenocarcinoma    | 32               | 40          | 80        | 20           | 20          | 100       |
| Large Cell        | 7                | 11          | 64        |              |             |           |

Source: [9,11,27]
ECTOPIC HORMONE PRODUCTION IN LUNG CANCER

2. Bornstein P, Nolan JP, Bernanke D: Adrenocortical hyperfunction in association with anaplastic carcinoma of the respiratory tract. New Engl J Med 264:363-371, 1961

3. Christy NP: Adrenocorticotropic activity in the plasma of patients with Cushing's syndrome associated with pulmonary neoplasms. Lancet 1:85-86, 1961

4. Meador CK, Liddle GW, Island DP, et al: Cause of Cushing's syndrome in patients with tumors arising from "nonendocrine" tissue. J Clin Endocrin Metab 22:693-703, 1965

5. Gilby ED, Rees LH, Bondy PK: Ectopic hormones as markers of response to therapy in cancer. Excerpta Medica International Congress Series Number 375. Proc Sixth Internatli Symposium on the Biological Characteristics of Human Tumours, 1976, pp 132-138

6. Gropp C, Havemann K, Scheuer A: Ectopic hormones in lung cancer patients at diagnosis and during therapy. Cancer 46:347-354, 1980

7. Hansen M, Hammer M, Hummer L: ACTH, ADH and calcitonin concentrations as markers of response and relapse in small-cell carcinoma of the lung. Cancer 46:2062-2067, 1980

8. Gewirtz G, Yalow RS: Ectopic ACTH production in carcinoma of the lung. J Clin Invest 53:1022-1032, 1974

9. Yalow RS, Eastridge CE, Higgins G Jr, et al: Plasma and tumor ACTH in carcinoma of the lung. Cancer 44:1789-1792, 1979

10. Hansen M, Hansen HH, Hirsch FR, et al: Hormonal polypeptides and amine metabolites in small cell carcinoma of the lung, with special reference to stage and subtypes. Cancer 45:1432-1437, 1980

11. Bloomfield GA, Holdaway IM, Corrin B, et al: Lung tumours and ACTH production. Clin Endocrin 6:95-104, 1977

12. Bondy PK, Gilby ED: Endocrine function in small cell undifferentiated carcinoma of the lung. Cancer, in press

13. Eagan RT, Maurer LH, Forcier RJ, et al: Small cell carcinoma of the lung: Staging, paraneoplastic syndromes, treatment and survival. Cancer 33:527-532, 1974

14. Gregor A, Morgan PGM, Morgan RL, et al: Small cell carcinoma: combined approach to treatment. Thorax 34:789-793, 1979

15. Amatruda TT Jr: Nonendocrine secreting tumors. In Diseases of Metabolism, 7th Edition. Edited by PK Bondy, LE Rosenberg. Philadelphia, WB Saunders Co, 1974, pp 1629-1650

16. Coombes RC, Hillyard C, Greenberg PB, et al: Plasma-immunoreactive-calcitonin in patients with non-thyroid tumours. Lancet 1:1080-1083, 1974

17. Becker KL, Snider RH, Silver OL, et al: Calcitonin heterogeneity in lung cancer and medullary thyroid cancer. Acta Endocrinol 89:89-99, 1978

18. Roos BA, Lindall AW, Baylin SB, et al: Plasma immunoreactive calcitonin in lung cancer. J Clin Endocrin Metab 50:659-666, 1980

19. Samaan NA, Castillo S, Schultz PN, et al: Serum calcitonin after pentagastrin stimulation in patients with bronchogenic and breast cancer compared to that in patients with medullary thyroid carcinoma. J Clin Endocrin Metab 51:237-241, 1980

20. Bender RA, Hansen H: Hypercalcemia in bronchogenic carcinoma. A prospective study of 200 patients. Ann Int Med 80:205-208, 1974

21. Gailani S, Chu TM, Nussbaum A, et al: Human chorionic gonadotrophins (hCG) in nontrophoblastic neoplasms. Assessment of abnormalities of hCG and CEA in bronchogenic and digestive neoplasms. Cancer 38:1684-1686, 1976

22. Hagen C, Gilby ED, McNeilly AS, et al: Comparison of circulating glycoprotein hormones and their subunits in patients with oat cell carcinoma of the lung and uraemic patients on chronic dialysis. Acta Endocrin 83:26-35, 1976

23. Pearse AGE: Neurocristopathy, neuroendocrine pathology and the APUD concept. Z Krebforsch 84:1-18, 1975

24. Spanos A, Spry CJ: Inappropriate secretion of antidiuretic hormone with chronic chest infections. Brit Med J 3:785-786, 1974

25. Bondy PK: The Adrenal Cortex. In Metabolic Control and Disease, 8th edition. Edited by PK Bondy, LE Rosenberg. Philadelphia, WB Saunders Co, 1980, pp 1427-1500

26. Hirata Y: Synthesis and secretion of ACTH and p-MSH by ectopic ACTH-producing tumors. Kobe J Med Sci 22:91-101, 1976

27. Odell WD, Wolfsen AR, Bachelot I, et al: Ectopic production of lipotropin by cancer. Am J Med 66:631-638, 1979

28. Schwartz KE, Wolfsen AR, Forster B, et al: Calcitonin in nonthyroidal cancer. J Clin Endocrin Metab 49:438-444, 1979

29. Yoshimoto Y, Wolfsen AR, Odell WD: Glycosylation, a variable in the production of hCG by cancers. Am J Med 7:414-420, 1979